首页> 美国卫生研究院文献>BioMed Research International >Decreased Plasma COMP and Increased Plasma CTX-II Levels in a Chinese Pseudoachondroplasia Family with Novel COMP Mutation
【2h】

Decreased Plasma COMP and Increased Plasma CTX-II Levels in a Chinese Pseudoachondroplasia Family with Novel COMP Mutation

机译:新型COMP突变在中国假性软骨发育不全家庭中血浆COMP降低和血浆CTX-II水平升高

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pseudoachondroplasia (PSACH) is an autosomal dominant osteochondrodysplasia caused by mutations in the gene encoding cartilage oligomeric matrix protein (COMP). Accurate clinical diagnosis of PSACH is sometimes difficult. Here, we identified a novel COMP mutation (c.1675G>A, p.Glu559Lys) in a Chinese PSACH family. We detected the plasma levels of COMP and type II collagen (CTX-II) in the four affected individuals. The results showed the levels of plasma COMP significantly decreased and plasma CTX-II significantly increased in the three PSACH patients with COMP mutation. However, both plasma levels of COMP and CTX-II were not to have found significant difference between the presymptomatic carrier and the age-matched subjects. In vitro analysis and immunofluorescence displayed wild type COMP homogenously expressed in cytoplasm, but mutant proteins were irregularly accumulated inside the HEK-293 cells. Western blot revealed that the quantity of the mutant COMP was more compared to wild type COMP in cells after transfection for 12 hours and 24 hours. Subsequently, 3D structural analysis showed three changes have taken place in secondary structure of the mutant COMP. In conclusion, the novel mutation of COMP may result in intracellular accumulation of the mutant protein. Decreased plasma COMP and increased plasma CTX-II may potentially serve as diagnostic markers of PSACH but may not be applicable in the presymptomatic carrier.
机译:伪软骨发育不良(PSACH)是一种常染色体显性遗传骨软骨发育不良,是由编码软骨寡聚基质蛋白(COMP)的基因突变引起的。有时很难对PSACH进行准确的临床诊断。在这里,我们在中国PSACH家族中鉴定了一个新的COMP突变(c.1675G> A,p.Glu559Lys)。我们检测了四个受影响个体的血浆COMP和II型胶原蛋白(CTX-II)的水平。结果显示,三名患有COMP突变的PSACH患者的血浆COMP水平显着降低,血浆CTX-II显着升高。然而,COMP和CTX-II的血浆水平在症状前携带者和年龄匹配的受试者之间均未发现显着差异。体外分析和免疫荧光显示野生型COMP在细胞质中均表达,但突变蛋白在HEK-293细胞内不规则地积累。 Western印迹显示,转染12小时和24小时后,细胞中突变型COMP的量比野生型COMP多。随后,3D结构分析表明突变体COMP的二级结构发生了三个变化。总之,COMP的新突变可能导致突变蛋白的细胞内积累。血浆COMP减少和血浆CTX-II升高可能潜在地成为PSACH的诊断标志物,但可能不适用于有症状的载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号